MX2021011524A - Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos. - Google Patents
Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos.Info
- Publication number
- MX2021011524A MX2021011524A MX2021011524A MX2021011524A MX2021011524A MX 2021011524 A MX2021011524 A MX 2021011524A MX 2021011524 A MX2021011524 A MX 2021011524A MX 2021011524 A MX2021011524 A MX 2021011524A MX 2021011524 A MX2021011524 A MX 2021011524A
- Authority
- MX
- Mexico
- Prior art keywords
- prmt5 inhibitors
- methods
- present disclosure
- inhibitors
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se refiere a compuestos de Fórmulas (I)-(V) y métodos para elaborar los mismos. Los compuestos de la presente descripción son útiles como inhibidores de la actividad de PRMT5 y en métodos para tratar cánceres y otras enfermedades. (ver Fórmula).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962823374P | 2019-03-25 | 2019-03-25 | |
US201962874773P | 2019-07-16 | 2019-07-16 | |
PCT/US2020/024654 WO2020198323A1 (en) | 2019-03-25 | 2020-03-25 | Prmt5 inhibitors and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021011524A true MX2021011524A (es) | 2021-12-15 |
Family
ID=72609147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021011524A MX2021011524A (es) | 2019-03-25 | 2020-03-25 | Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220194949A1 (es) |
EP (1) | EP3947387A4 (es) |
JP (1) | JP2022521818A (es) |
KR (1) | KR20220023330A (es) |
CN (1) | CN114127072A (es) |
AU (1) | AU2020245480A1 (es) |
BR (1) | BR112021019125A2 (es) |
CA (1) | CA3134779A1 (es) |
IL (1) | IL286622A (es) |
MX (1) | MX2021011524A (es) |
SG (1) | SG11202110272SA (es) |
WO (1) | WO2020198323A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
EP4188920A1 (en) | 2020-07-31 | 2023-06-07 | Tango Therapeutics, Inc. | Piperidin-1-yl-n-pyrydine-3-yl-2-oxoacetamide derivatives useful for the treatment of mtap-deficient and/or mta-accumulating cancers |
WO2023001133A1 (zh) * | 2021-07-20 | 2023-01-26 | 上海齐鲁制药研究中心有限公司 | Prmt5抑制剂 |
WO2023127857A1 (ja) * | 2021-12-27 | 2023-07-06 | 株式会社理研ジェネシス | 新規人工核酸、その製造方法及び用途 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6143749A (en) * | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
US6875751B2 (en) | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
KR102158756B1 (ko) * | 2013-03-14 | 2020-09-23 | 에피자임, 인코포레이티드 | 아르기닌 메틸기 전이효소 억제제 및 이의 용도 |
MX2017010844A (es) * | 2015-02-24 | 2017-12-07 | Pfizer | Derivados de nucleosidos sustituidos utiles como agentes anticancerosos. |
TWI791251B (zh) * | 2015-08-26 | 2023-02-01 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
CA3016096C (en) * | 2016-03-10 | 2023-10-17 | Janssen Pharmaceutica Nv | Substituted nucleoside analogues for use as prmt5 inhibitors |
WO2018065365A1 (en) * | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
WO2018160824A1 (en) * | 2017-03-01 | 2018-09-07 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
EP3665179B1 (en) * | 2017-08-09 | 2021-06-09 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
EP4385996A2 (en) * | 2017-12-08 | 2024-06-19 | JANSSEN Pharmaceutica NV | Novel spirobicyclic analogues |
-
2020
- 2020-03-25 KR KR1020217034437A patent/KR20220023330A/ko unknown
- 2020-03-25 SG SG11202110272SA patent/SG11202110272SA/en unknown
- 2020-03-25 CA CA3134779A patent/CA3134779A1/en active Pending
- 2020-03-25 MX MX2021011524A patent/MX2021011524A/es unknown
- 2020-03-25 WO PCT/US2020/024654 patent/WO2020198323A1/en unknown
- 2020-03-25 CN CN202080037608.5A patent/CN114127072A/zh active Pending
- 2020-03-25 US US17/598,152 patent/US20220194949A1/en active Pending
- 2020-03-25 JP JP2021557342A patent/JP2022521818A/ja active Pending
- 2020-03-25 EP EP20778402.6A patent/EP3947387A4/en active Pending
- 2020-03-25 AU AU2020245480A patent/AU2020245480A1/en active Pending
- 2020-03-25 BR BR112021019125A patent/BR112021019125A2/pt unknown
-
2021
- 2021-09-23 IL IL286622A patent/IL286622A/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL286622A (en) | 2021-12-01 |
CN114127072A (zh) | 2022-03-01 |
SG11202110272SA (en) | 2021-10-28 |
AU2020245480A1 (en) | 2021-11-11 |
CA3134779A1 (en) | 2020-10-01 |
US20220194949A1 (en) | 2022-06-23 |
WO2020198323A1 (en) | 2020-10-01 |
JP2022521818A (ja) | 2022-04-12 |
EP3947387A4 (en) | 2022-11-30 |
EP3947387A1 (en) | 2022-02-09 |
BR112021019125A2 (pt) | 2021-11-30 |
KR20220023330A (ko) | 2022-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021001186A (es) | Purinonas como inhibidores de proteasa especifica de ubiquitina 1. | |
MX2021011524A (es) | Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos. | |
MX2021013662A (es) | Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos. | |
MX2023005804A (es) | Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7). | |
MX2022004513A (es) | Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr). | |
MX2021013661A (es) | Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos. | |
MX2022002938A (es) | Compuestos inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) cooperativos para metiltioadenosina (mta). | |
MX2021011209A (es) | Novedosos inhibidores de molécula pequeña de factores de transcripción tead. | |
MX2022004390A (es) | Aminas biciclicas como inhibidores de la cinasa dependiente de ciclina 2 (cdk2). | |
MX2023010430A (es) | Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten con mutacion g12d (kras g12d). | |
AU2018347307A1 (en) | Heterocyclic compounds and uses thereof | |
PH12021550382A1 (en) | Tetrahydropyridopyrimidine derivatives as ahr modulators | |
MX2022001019A (es) | Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38). | |
EA201790502A1 (ru) | Ингибиторы гистоновых диметилаз | |
MX2022001004A (es) | Inhibidores de enzimas. | |
MX2023010429A (es) | Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten (kras). | |
PH12019502049A1 (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
MX2021016049A (es) | Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas. | |
MX2022000310A (es) | Inhibidores de proteina bcl-2. | |
WO2019023315A3 (en) | RAC INHIBITORS | |
AU2020258568A8 (en) | CD73 inhibitors | |
MX2021009426A (es) | Derivados de indazolil-isoxazol para el tratamiento de enfermedades tales como cancer. | |
WO2018183370A3 (en) | Kdm4 inhibitors | |
MX2021015628A (es) | Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso. | |
MX2021012418A (es) | Compuestos heterociclicos y sus usos. |